These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 34519141)
41. Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation. Sharma G; Mahler DA; Mayorga VM; Deering KL; Harshaw O; Ganapathy V Chronic Obstr Pulm Dis; 2017 Jul; 4(3):217-224. PubMed ID: 28848933 [No Abstract] [Full Text] [Related]
42. Prevalence and Associated Factors of Suboptimal Daily Peak Inspiratory Flow and Technique Misuse of Dry Powder Inhalers in Outpatients with Stable Chronic Airway Diseases. Ding N; Zhang W; Wang Z; Bai C; He Q; Dong Y; Feng X; Zhang J; Gao S Int J Chron Obstruct Pulmon Dis; 2021; 16():1913-1924. PubMed ID: 34188467 [TBL] [Abstract][Full Text] [Related]
43. Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair Yildiz P; Bayraktaroglu M; Gorgun D; Secik F Int J Chron Obstruct Pulmon Dis; 2016; 11():2859-2867. PubMed ID: 27920513 [TBL] [Abstract][Full Text] [Related]
44. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder. Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621 [TBL] [Abstract][Full Text] [Related]
45. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? Dahl R; Kaplan A BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909 [TBL] [Abstract][Full Text] [Related]
46. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Ram FS; Carvallho CR; White J Int J Chron Obstruct Pulmon Dis; 2011; 6():129-39. PubMed ID: 21468167 [TBL] [Abstract][Full Text] [Related]
47. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients. Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137 [TBL] [Abstract][Full Text] [Related]
49. Aerosol delivery of inhalation devices with different add-on connections to invasively ventilated COPD subjects: An in-vivo study. Seif SM; Ma E; Rabea H; Saeed H; Abdelrahim MEA Eur J Pharm Sci; 2021 Dec; 167():105988. PubMed ID: 34492291 [TBL] [Abstract][Full Text] [Related]
50. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. Chodosh S; Flanders JS; Kesten S; Serby CW; Hochrainer D; Witek TJ J Aerosol Med; 2001; 14(3):309-15. PubMed ID: 11693842 [TBL] [Abstract][Full Text] [Related]
51. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Broeders ME; Molema J; Vermue NA; Folgering HT Eur Respir J; 2001 Nov; 18(5):780-3. PubMed ID: 11757627 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease. Leaker BR; Singh D; Nicholson GC; Hezelova B; Goodin T; Ozol-Godfrey A; Galluppi G; Barnes PJ Respir Res; 2019 Jun; 20(1):132. PubMed ID: 31253162 [TBL] [Abstract][Full Text] [Related]
53. Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair Yildiz P; Bayraktaroglu M; Gorgun D; Yuksel K Clin Drug Investig; 2019 Oct; 39(10):991-1001. PubMed ID: 31332649 [TBL] [Abstract][Full Text] [Related]
54. Ability of using different dry powder inhalers during COPD exacerbations. Papaioannou AI; Herodotou Y; Tomos I; Apollonatou V; Verykokou G; Papathanasiou E; Manali ED; Loukides S; Papiris SA Pulm Pharmacol Ther; 2018 Feb; 48():211-216. PubMed ID: 29277688 [TBL] [Abstract][Full Text] [Related]
55. Investigation of Appropriate Inhalation Technique for Mometasone Furoate Dry Powder Inhaler. Yokoyama H; Ito K; Mihashi H; Shiraishi Y; Takayanagi R; Yamada Y Biol Pharm Bull; 2016; 39(10):1576-1580. PubMed ID: 27725433 [TBL] [Abstract][Full Text] [Related]
56. Establishment of relationships between native and inhalation device specific spirometric parameters as a step towards patient tailored inhalation device selection. Farkas Á; Szipőcs A; Horváth A; Horváth I; Gálffy G; Varga J; Galambos K; Kugler S; Nagy A; Szalai Z Respir Med; 2019; 154():133-140. PubMed ID: 31252206 [TBL] [Abstract][Full Text] [Related]
57. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data. Müller V; Gálffy G; Orosz M; Kováts Z; Odler B; Selroos O; Tamási L Int J Chron Obstruct Pulmon Dis; 2016; 11():93-101. PubMed ID: 26834466 [TBL] [Abstract][Full Text] [Related]
58. Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers. Boshra MS; Almeldien AG; Salah Eldin R; Elberry AA; Abdelwahab NS; Nabil Salem M; Rabea H; Abdelrahim MEA Exp Lung Res; 2018; 44(4-5):211-216. PubMed ID: 30346848 [TBL] [Abstract][Full Text] [Related]
59. Effect of different accessory devices on the dose delivered from pressurised metred-dose inhalers. Nicola M; Hussein RRS; Soliman YMA; Abdelrahim M Int J Clin Pract; 2021 Jun; 75(6):e14157. PubMed ID: 33763954 [TBL] [Abstract][Full Text] [Related]
60. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD. Molimard M; Till D; Stenglein S; Singh D; Krummen M Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]